At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 463 enrolled
Drug / intervention
Galcanezumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the CONQUER Study
In Brief
A Phase 3 clinical trial evaluating Galcanezumab and Placebo for Migraine. Completed, enrolled 463 participants across 69 sites in 13 countries.
Detailed Summary
The purpose of this study is to assess the safety and efficacy of galcanezumab in people with treatment-resistant episodic or chronic migraine.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
CountriesBelgium, Canada, Czechia, France, Germany, Hungary, Japan, Netherlands, Puerto Rico, South Korea, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedJun 2018
Enrollment StartJul 2018
Primary CompletionJun 2019
Study CompletionSep 2019
TodayJul 2026
First PostedJun 18, 2018
Enrollment StartJul 31, 2018
Primary CompletionJun 19, 2019
Study CompletionSep 19, 2019
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 8.0 years ago
Interventions
Galcanezumabdrug
Administered SC.
Placebodrug
Administered SC.